

SHCP APC Summary

Date: May 2023

Link to the full May SHCP APC minutes are available [HERE](#)

SHCP APC item	Summary of decision
PETRUSHKA study	Approved vortioxetine, paroxetine and fluvoxamine are approved for use by GPs who prescribe them as part of their participation in the PETRUSHKA study. This is a research study in primary care that is looking at the initial prescribing of antidepressants and the choice of antidepressants using a web-based tool.
Solifenacin (Vesicare®) 1mg/ml oral suspension sugar free suspension formulary extension	Approved with a GREEN formulary coding (non-specialist initiation) first line in swallowing difficulties. This is a long-acting anticholinergic once a day medicines, it clinically has less of an anticholinergic burden compared to the alternative liquid preparations available. Overactive Bladder (OAB) pathway
Dexamfetamine 5mg in 5ml sugar free oral solution.	Not approved the decision-making framework highlighted concerns regarding cost-effectiveness, the committee are unsure of the place in the treatment pathway, and concerns raised around the equity.
Methylphenidate - Delmosart® prolonged release tablets and Ritalin® XL capsules (all strengths)	Not approved the decision-making framework highlighted concerns regarding cost-effectiveness, the committee are unsure of the place in the treatment pathway, and concerns raised around the equity.
Oral Semaglutide	Approved with a GREEN second-line alternative to the subcutaneous GLP-1 agonists in those patients who are: <ul style="list-style-type: none"> • unable to tolerate the injectable preparation of GLP-1, or • psychologically unable to inject, or • unable to self-administer an injection due to physical disability or dexterity problems.
Previously approved Shared Care Protocols	To note on the Sussex Partner Formulary that ' <i>Prescribing should be undertaken in accordance with the Sussex Partner Formulary</i> ' to all previously approved Shared Care Protocols.
Virtual approval	
SHCP APC Operating Framework and submission guidance	The APC noted the production and availability of the APC operating framework and the APC submission guidance for applicants. The APC Secretariat now has in place robust documentation that underpins the resilient operation of the APC and helps support submission of items to the committee.
Bevespi summary report	The APC noted that there has been a small increase of prescribing of Bevespi MDI since it has been approved

	to be put on the Sussex Partner formulary. However, Bevespi only makes up 1-2% of all LABA/LAMAs prescribed in Sussex meaning the vast majority are DPIs.
SHCP APC Liothyronine Shared Care Protocol	Approved amendment to the Liothyronine Shared Care Protocol to include the capsule formulation.
Amendments to the suspected Deep Vein Thrombosis (lower limb) LCS treatment pathway	Approved The Sussex DVT LCS treatment pathway to be amended to highlight the need to use apixaban or rivaroxaban as a first line DOAC, in line with NICE guidance, unless AMU/SDEC recommend LMWH. DVT LCS treatment pathway
Persistent bleeding on HRT pathway	Approved from a medicine's optimisation perspective noting alignment to current formulary positions, prior to full guidance final system sign-off.
NICE Technology Appraisals	
NICE TA873 Cannabidiol for treating seizures caused by tuberous sclerosis complex	Approved RED formulary coding
NICE TA876 Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer	Approved RED formulary coding
NICE TA877 Finerenone for treating chronic kidney disease in type 2 diabetes	Approved PURPLE formulary coding
NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating covid-19	Approved RED formulary coding
NICE TA880 Tezepelumab for treating severe asthma	Approved RED formulary coding
NICE TA879 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment	Terminated appraisal
NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19	Approved RED formulary coding
NICE TA875 Semaglutide for managing overweight and obesity	A red formulary status was allocated, given we do not know what the weight loss service commissioning landscape will be in Sussex at the point the product is made available. When Wegovy® is made available a paper will be presented to the APC summarising the implementation plan, with an approval request for the most appropriate formulary status at that point in time.

NICE Guidelines	
NG101 Early and locally advanced breast cancer: diagnosis and management (updated)	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
NG133 Hypertension in pregnancy: diagnosis and management (updated)	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
CG104 Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (updated)	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
New BlueTeq forms	
March 2023	
Somatrogon - Growth Disturbance in people 3 years and over (TA863) – INITIATION form	
Somatrogon - Growth Disturbance in people 3 years and over (TA863) – CONTINUATION form	
Avatrombopag - Refractory Primary Chronic Immune Thrombocytopenia (ITP) (TA853) – INITIATION form	
Avatrombopag - Refractory Primary Chronic Immune Thrombocytopenia (ITP) (TA853) – CONTINUATION form	
Upadacitinib - Active Non-radiographic Axial Spondyloarthritis (TA861) – CONTINUATION form	
Upadacitinib - Active Non-radiographic Axial Spondyloarthritis (TA861) – INITIATION form	
May 2023	
Upadacitinib - Ulcerative Colitis - moderately to severely active (TA856) – CONTINUATION form	
Upadacitinib - Ulcerative Colitis- moderately to severely active (TA856) – INITIATION form	
Eptinezumab - Prevention of Migraine (TA871) – INITIATION form	
Eptinezumab - Prevention of Migraine (TA871) – CONTINUATION form	
DISCONTINUATIONS	
Date not specified	Pregestimil®
November 2022	Pregestimil Lipil®
March 2023	Normacol® and Normacol Plus® Nutilis® Powder Resource ThickenUp® Venlafaxine (Venlalic®) XL 37.5mg tablets
April 2023	Abelcet® 100mg/20mg concentrate for suspension for infusion vials SLO milkshakes (not discontinued but removed from Drug Tariff)
May 2023	Insuman Rapid® Cartridges
June 2023	Dalteparin 10,000units/1ml Solution for Injection Ampoules (1st June 2023)